FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EOVIST (gadoxetate disodium) to expand/update its labeling for MRI imaging of focal liver lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Diseases
• Liver Neoplasms

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

SUPPL AP for EOVIST (GADOXETATE DISODIUM)